Compare MNOV & PGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNOV | PGP |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 102.9M |
| IPO Year | 2005 | N/A |
| Metric | MNOV | PGP |
|---|---|---|
| Price | $1.28 | $8.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 76.3K | 39.8K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.84% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,917.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.13 | $5.83 |
| 52 Week High | $2.20 | $7.81 |
| Indicator | MNOV | PGP |
|---|---|---|
| Relative Strength Index (RSI) | 33.65 | 62.10 |
| Support Level | $1.48 | $8.52 |
| Resistance Level | $1.51 | $8.91 |
| Average True Range (ATR) | 0.05 | 0.11 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 0.00 | 93.59 |
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.